Table 3.

Patterns of vascular endothelial growth factor (VEGF)‐A changes following treatment predicts benefit from cediranib

Biomarker name	P‐value	Hazard ratio	95% CI
ECOG PS	0.04	2.05	1.05–3.98
Tie2 *	0.01	0.61	0.42–0.89
VEGF‐A pretreatment **	0.01	1.13	1.04–1.23
Treatment	0.07	5.70	0.88–37.14
VEGF‐A pretreatment: Treatment ***	0.01	0.83	0.71–0.96
VEGF‐A elevation	0.08	2.43	0.91–6.51
VEGF‐A elevation: Treatment ***	0.02	0.13	0.02–0.71

^* log2 transformed due to non‐linearity.

^** VEGF‐A divided by 100.

^*** interaction between a biomarker and treatment, representing the predictive significance of the biomarker.

ECOG PS, Eastern Cooperative Oncology Group performance status